First Tracks Biotherapeutics Inc stock analysis
Want to see TRAX full AI Analyst Report?
First Tracks Biotherapeutics Inc (TRAX) Stock Price & Analysis
TRAX Stock Chart & Stats
- Day’s Range
- $43.80 - $46.27
- 52-Week Range
- $14.72 - $54.78
- Previous Close
- $44.50
- Volume
- N/A
- Average Volume (3M)
- 962.59K
- Market Cap
- $1.87B
- Enterprise Value
- $1.12B
- Total Cash (Recent Filing)
- $155.63M
- Total Debt (Recent Filing)
- $3.77M
- Price to Earnings (P/E)
- ―
- Beta
- 0.48
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation
Positive Phase 1b efficacy and tolerability data provide clinical validation for ANB033 and support progression toward later-stage development. If confirmed in subsequent studies, this evidence could strengthen the company’s product prospects and improve its ability to address an unmet need in celiac disease.
Low Financial Leverage
Very low debt relative to equity limits interest and repayment burdens compared with a highly leveraged biotech structure. This gives the company greater financial flexibility to direct available resources toward research and development, although it does not eliminate the need for future funding.
Pipeline Expansion
Plans to test ANB033 across celiac disease, vitiligo, and another indication broaden the potential application of the lead program. Multiple development paths can diversify clinical opportunity and create more avenues for future value if efficacy is demonstrated across diseases.
Bears Say
No Commercial Revenue
The absence of revenue means the company currently lacks a commercial funding engine and remains dependent on capital markets or other financing sources. Negative gross profit and ongoing development spending also indicate that commercial self-sufficiency is not yet established.
Worsening Losses
Large and worsening net losses show that operating costs are rising faster than any offsetting income, leaving profitability structurally distant. Continued losses can reduce the capital available for development and increase the financial resources required before programs can generate returns.
Heavy Cash Burn And Funding Risk
Accelerating operating cash outflows demonstrate that reported losses are translating into substantial real cash consumption. Persistently negative free cash flow implies ongoing funding needs, while reliance on additional financing can constrain strategic flexibility and create dilution pressure.
First Tracks Biotherapeutics Inc News
Analyst Raises First Tracks Biotherapeutics Price Target to $60 on Strong ANB033 Clinical Results and Expanded Pipeline
Canaccord Genuity analyst Edward Nash has reiterated their bullish stance on TRAX stock, giving a Buy rating today. Edward Nash has given his Buy rating due to a combination of
First Tracks Biotherapeutics reports results from Cohort 1 of ANB033 trial
First Tracks Biotherapeutics (TRAX) announced top-line results from Cohort 1 of ANB033’s Phase 1b trial in celiac disease, or CeD. ANB033, an investigational, subcutaneously administered CD122 antagonist, is designed to
Edward Nash Reiterates Buy on First Tracks Biotherapeutics, Maintains $50 Price Target Amid Growing Confidence in ANB033 Program
Canaccord Genuity analyst Edward Nash has reiterated their bullish stance on TRAX stock, giving a Buy rating today. Edward Nash has given his Buy rating due to a combination of
TRAX FAQ
What was First Tracks Biotherapeutics Inc’s price range in the past 12 months?
What is First Tracks Biotherapeutics Inc’s market cap?
When is First Tracks Biotherapeutics Inc’s upcoming earnings report date?
How were First Tracks Biotherapeutics Inc’s earnings last quarter?
Is First Tracks Biotherapeutics Inc overvalued?
Does First Tracks Biotherapeutics Inc pay dividends?
What is First Tracks Biotherapeutics Inc’s EPS estimate?
How many shares outstanding does First Tracks Biotherapeutics Inc have?
What happened to First Tracks Biotherapeutics Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of First Tracks Biotherapeutics Inc?
What is the TipRanks Smart Score and how is it calculated?
First Tracks Biotherapeutics Inc Stock Smart Score
Company Description
First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel R. Faga
- Employees
- 104
- Website
- www.firsttracksbio.com
- Address
- 10770 Wateridge Circle, San Diego, CA, 92121, US
First Tracks Biotherapeutics Inc (TRAX) Earnings & Revenues
TRAX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 4 | 8 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 4 | 0 | 6 |










